Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

search marketing

- PMLiVE

Infographic: Rare Diseases in China

How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.

Research Partnership

- PMLiVE

Webcast: China Update 2023: How will recent developments impact your brand’s success?

Register for this live webinar in which emerging market experts provide an update regarding the implications of changing demographics and the healthcare landscape.

Research Partnership

- PMLiVE

Sanofi and Innovent Biologics to develop oncology drugs for patients in China

Sanofi will make an initial equity investment of €300m in Innovent

- PMLiVE

Novo Nordisk growth takes a hit with China deal

Danish diabetes specialist Novo Nordisk cuts its growth forecast for 2022 following a value-based procurement deal with the Chinese government for its insulin products

- PMLiVE

Sinopharm’s COVID-19 vaccine scores approval in China

Vaccine found to be 79% effective in top-line results

Webcast

China: How pharma can maximize success in this rapidly changing emerging market

Research Partnership

China flag thumb

Experimental Chinese COVID-19 vaccine is safe, according to researchers

Safety data was published on pre-print server medRxiv

Impetus Digital Fireside Chat with Tom Hsu, VP, Specialty Medicine at Bayer Canada

Tom Hsu, VP of Specialty Medicine at Bayer Canada,  talks about how he got to where he is today and his experience working for Bayer in China, and how that compares to...

Impetus Digital

- PMLiVE

China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances

China secures a place at the forefront of innovative medicine

Roche Basel Switzerland

China backs use of Roche’s Actemra for coronavirus

Anti-inflammatory drug will be used in patients with lung complications

- PMLiVE

India’s export curbs raise fears of global drug shortages

Decision comes amid increased concerns over coronavirus outbreak

- PMLiVE

Roche’s PD-L1 inhibitor Tecentriq approved in China for SCLC

Solidifies immunotherapy drug's dominance in the setting

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links